Diversity of the angiogenic phenotype in non-small cell lung cancer

被引:27
|
作者
McClelland, Marc R.
Carskadon, Shannon L.
Zhao, Liujian
White, Eric S.
Beer, David G.
Orringer, Mark B.
Pickens, Allan
Chang, Andrew C.
Arenberg, Douglas A.
机构
[1] Univ Michigan, Ctr Med, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ctr Med, Dept Surg, Sect Gen Thorac Surg, Ann Arbor, MI 48109 USA
关键词
angiogenesis; mouse model; chemokines; cytokines; carcinogen;
D O I
10.1165/rcmb.2006-0311OC
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Angiogenesis is crucial for tumor biology. There are many mechanisms by which tumors induce angiogenesis. We hypothesize that each individual tumor develops a unique mechanism to induce angiogenesis, and that activation of a particular angiogenic pathway suppresses the evolution of alternative pathways. We characterized 168 human non-small cell lung cancer (NSCLC) specimens for levels of angiogenic factors (angiogenic CXC chemokines, basic fibroblast growth factor, and vascular endothelial growth factor). We also induced lung tumor formation in A/J mice by injecting the tobacco carcinogen NNK. We dissected individual lung tumors and measured expression of angiogenic factors from three distinct families using real-time PCR. Finally, we controlled the angiogenic milieu using in vivo models to determine the resultant phenotype of the angiogenic factors expressed by NSCLC cells. Human tumors displayed marked variation in the expression of angiogenic factors. Individual mouse tumors, even from within the same mouse, displayed variability in their pattern of expression of angiogenic factors. In a sponge model of angiogenesis using murine lung cancer cells, implanting LLC cells with an angiogenic factor suppressed the expression of other angiogenic factors in implanted sponges. This suppressive effect was not seen in vitro. We conclude that lung cancer tumors evolve a unique and dominant angiogenic phenotype. Once an angiogenic pathway is activated, it may allow for tumor growth to proceed in the absence of a selection pressure to activate a second pathway.
引用
收藏
页码:343 / 350
页数:8
相关论文
共 50 条
  • [41] NON-SMALL CELL LUNG-CANCER
    HASKELL, CM
    HOLMES, EC
    CURRENT PROBLEMS IN CANCER, 1987, 11 (01) : 1 - 53
  • [42] Vinorelbine for non-small cell lung cancer
    Piccirillo, Maria Carmela
    Daniele, Gennaro
    Di Maio, Massimo
    Bryce, Jane
    De Feo, Gianfranco
    Del Giudice, Antonia
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT OPINION ON DRUG SAFETY, 2010, 9 (03) : 493 - 510
  • [43] Angiogenesis and non-small cell lung cancer
    Cox, G
    Jones, JL
    Walker, RA
    Steward, WP
    O'Byrne, KJ
    LUNG CANCER, 2000, 27 (02) : 81 - 100
  • [44] Immunotherapy for Non-Small Cell Lung Cancer
    Yoon, Sung Ho
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2014, 77 (03) : 111 - 115
  • [45] SURGERY FOR NON-SMALL CELL LUNG CANCER
    Vrtik, Marosh
    Alam, Naveed Z.
    CANCER FORUM, 2013, 37 (02) : 150 - 153
  • [46] Oligoprogression in Non-Small Cell Lung Cancer
    Harada, Daijiro
    Takigawa, Nagio
    CANCERS, 2021, 13 (22)
  • [47] Screening for non-small cell lung cancer
    Ashton, RW
    Jett, JR
    SEMINARS IN ONCOLOGY, 2005, 32 (03) : 253 - 258
  • [48] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [49] The lymphadenectomy in non-small cell lung cancer
    Chiappetta, Marco
    VIDEO-ASSISTED THORACIC SURGERY, 2022, 7
  • [50] Paclitaxel for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) : 1771 - 1780